Codify — Article

Medicare bill mandates cognitive impairment detection at AWV and initial exam

SB1799 requires Medicare providers to screen for cognitive impairment during the Annual Wellness Visit and the Welcome-to-Medicare exam using NIA‑approved tools and to record results in the medical record.

The Brief

This bill inserts cognitive impairment detection into two standard Medicare preventive encounters: the Annual Wellness Visit (AWV) and the initial preventive physical examination (commonly called the Welcome-to-Medicare visit). The change is intended to surface undiagnosed dementia or mild cognitive impairment earlier so patients and caregivers can access planning, supports, and treatments sooner.

The policy matters because it makes cognitive detection a routine, statutory element of Medicare prevention visits for beneficiaries — potentially increasing diagnosis rates, shifting workload to primary care, and creating new documentation and operational requirements for providers and health systems.

At a Glance

What It Does

SB1799 amends Title XVIII of the Social Security Act to require that Medicare AWVs and initial preventive physical exams include detection of any cognitive impairment using cognitive assessment instruments identified by the National Institute on Aging (NIA) as meeting its primary‑care criteria, and it requires recording the tool used and the assessment results in the beneficiary’s medical record.

Who It Affects

Primary care clinicians and other Medicare‑authorized providers who furnish AWVs and Welcome‑to‑Medicare exams, practice managers and EHR teams responsible for documentation workflows, Medicare contractors and CMS for oversight, and Medicare beneficiaries and their caregivers who may receive new or earlier cognitive assessments.

Why It Matters

By codifying a screening requirement and tying it to an NIA‑vetted instrument list, the bill sets a national standard for how cognitive risk is detected in Medicare’s preventive visits — shifting expectations for clinical practice, recordkeeping, and downstream referral patterns without specifying additional Medicare payment or federal implementation funding.

More articles like this one.

A weekly email with all the latest developments on this topic.

Unsubscribe anytime.

What This Bill Actually Does

SB1799 changes statutory language in the Social Security Act so that two Medicare preventive touchpoints — the Annual Wellness Visit (AWV) and the initial preventive physical examination (IPPE) — include a mandated check for cognitive impairment. For the AWV it replaces the existing subparagraph that describes detection with a requirement that detection be performed using one of the instruments identified by the National Institute on Aging as appropriate for primary care, and that the provider document both which tool was used and the results in the medical record.

For the IPPE it adds the same detection requirement into the list of elements the clinician must address.

The law names the NIA’s list of instruments as the benchmark; it does not itself select specific tests, change CPT codes, or authorize a new payment. The bill sets a clear effective date for the new requirement: both changes apply to services furnished on or after January 1, 2026.

That creates a finite implementation window for CMS and providers to update policies, training, and electronic templates.Operationally, clinicians will need to pick an NIA‑endorsed instrument that fits their workflow (brief verbal screens, performance tasks, or informant questionnaires), build it into the AWV/IPPE encounter, and record both tool and result in the chart. Practices will confront tradeoffs: adding 5–15 minutes to a visit or shifting tasks to nursing or medical assistants, building EHR fields for discrete results, and deciding when a positive screen triggers further evaluation or referral to neurology, geriatrics, or behavioral health.

Payers and systems should expect changes in referral volumes and documentation patterns; CMS will need to issue guidance on acceptable instruments, documentation standards, and whether performance will be audited as part of existing oversight activities.

The Five Things You Need to Know

1

The bill amends 42 U.S.C. 1395x(hhh)(2) by replacing subparagraph (D) to require cognitive impairment detection as part of the Annual Wellness Visit.

2

It amends 42 U.S.C. 1395x(ww)(1) to add the same cognitive detection requirement to the initial preventive physical examination (Welcome‑to‑Medicare visit).

3

Detection must use one of the cognitive assessment instruments identified by the National Institute on Aging as meeting criteria for primary‑care settings, but the statute defers to the NIA list rather than naming specific tests.

4

Providers must document both which instrument they used and the screening results in the patient’s medical record; the bill does not define a minimum data format or coding standard for that documentation.

5

Both provisions become effective for services furnished on or after January 1, 2026, and the bill does not appropriate funding or add a separate Medicare payment for the additional screening or training.

Section-by-Section Breakdown

Every bill we cover gets an analysis of its key sections. Expand all ↓

Section 1

Findings on Alzheimer’s and dementia burden

This section compiles a series of findings about the scale and projected growth of Alzheimer’s disease and related dementias, demographic disparities (racial and sex differences), caregiver burden, and projected costs to the health system. The findings provide the statutory rationale for treating earlier detection as a public‑health priority; they are framing language rather than operative requirements but signal congressional intent that early identification and risk‑factor management matter for Medicare policy.

Section 2(a) — Amendment to Annual Wellness Visit (42 U.S.C. 1395x(hhh)(2))

Requires cognitive impairment detection at AWV and charting of tool/results

This provision replaces the existing AWV subparagraph on cognitive impairment detection with a mandatory requirement that detection be performed using an instrument from the NIA’s list and that the provider document the instrument and results in the beneficiary’s medical record. Practically, this converts a previously optional or variably performed assessment into a statutory element of the AWV and creates a concrete documentation duty for providers and their EHR systems.

Section 2(b) — Amendment to Initial Preventive Physical Examination (42 U.S.C. 1395x(ww)(1))

Incorporates the same cognitive detection requirement into the Welcome‑to‑Medicare exam

This clause inserts a requirement that the IPPE include cognitive impairment detection as described in the newly revised AWV provision. The text modifies the statutory list of IPPE elements rather than creating a standalone new benefit, aligning Welcome‑to‑Medicare with the AWV approach. Like the AWV change, it becomes effective for services on or after January 1, 2026.

At scale

This bill is one of many.

Codify tracks hundreds of bills on Healthcare across all five countries.

Explore Healthcare in Codify Search →

Who Benefits and Who Bears the Cost

Every bill creates winners and losers. Here's who stands to gain and who bears the cost.

Who Benefits

  • Medicare beneficiaries at risk of dementia — earlier detection creates opportunities for timely care planning, risk‑factor modification, medication assessment, and connection to community supports.
  • Family caregivers — documented early diagnoses can unlock counseling, respite planning, and more predictable care coordination.
  • Public health and research communities — a standardized, NIA‑anchored approach to screening in Medicare visits should generate more consistent prevalence and detection data across primary‑care settings, improving surveillance and recruitment for trials.
  • Health systems and clinicians seeking standardization — practices that already use validated cognitive screens gain a statutory anchor to justify workflow investment and resource allocation.

Who Bears the Cost

  • Primary care clinicians and practices — they will absorb time, training, and documentation burdens to perform validated screens and record results, particularly small and rural practices with constrained staffing.
  • Electronic health record vendors and health IT teams — they will need to add structured fields and templates to capture which instrument was used and the results in a retrievable way.
  • Medicare/ CMS — the agency will incur administrative costs to issue implementation guidance, potentially update manuals, and manage oversight or audits tied to the new documentation requirement.
  • Specialty services (neurology, geriatrics, behavioral health) — these providers may face increased referral volume from positive screens, with downstream capacity and access effects.

Key Issues

The Core Tension

The central dilemma is between the public‑health upside of routine, standardized cognitive detection (earlier diagnosis, better planning, reduced unmet needs) and the practical burdens it imposes on clinicians, EHR systems, and specialty services — especially since the bill mandates screening and documentation but does not fund training, reimburse additional clinician time, or set standards for follow‑up care.

The bill sets a national expectation for cognitive detection in two Medicare preventive visits but leaves key implementation choices unresolved. It defers instrument selection to the NIA list, which is sensible for clinical validity but raises practical questions about which instruments are permissible for multi‑lingual populations, for patients with low education or sensory impairment, and for proxy versus direct testing.

The statute requires documentation of the tool and result but does not specify data standards, discrete coding elements, or whether a positive screen triggers mandated follow‑up steps or referrals. That ambiguity will force CMS to issue clarifying guidance or risk inconsistent implementation across contractors and providers.

Another unresolved issue is financing. The bill does not create a new Medicare payment or adjust existing AWV/IPPE reimbursement, so the time and training costs fall to providers.

That could discourage thorough screening in resource‑constrained practices or push screening tasks onto non‑clinician staff, which has implications for test fidelity. Finally, increased screening will produce more false positives and more diagnostic workups; without parallel investment in specialty capacity and dementia care pathways, earlier detection could create bottlenecks and unequal follow‑through that exacerbate, rather than reduce, disparities the findings highlight.

Try it yourself.

Ask a question in plain English, or pick a topic below. Results in seconds.